Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Inflammatory Disease Development, with a focus on human-specific CHRFAM7A biology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHRNA7/CHRFAM7A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHRNA7 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CHRNA7 Products |
| Gene Delivery (CHRNA7) | CHRNA7 Full-Length Lentivirus Sequence Verified, CMV promoter, Puromycin selection, Endotoxin <1EU/ug. |
View CHRNA7 Products |
| Gene Delivery (CHRFAM7A) | CHRFAM7A (dupα7) Full-Length Lentivirus Human-specific fusion isoform for dominant negative mechanism studies. Sequence Verified. |
View CHRFAM7A Products |
| Co-expression System | CHRNA7/CHRFAM7A Dual Lentivirus Set Optimized ratio for dominant negative interaction assays in human cell lines. |
View CHRNA7 Products |
| Benchmark Ab | Anti-CHRNA7 (Sequence of Benchmark Modulator) Recombinant positive control. |
View CHRNA7 Products |
| Validator (CHRNA7) | CHRNA7 siRNA Set For knockdown verification and specificity controls. |
View CHRNA7 Products |
| Validator (CHRFAM7A) | CHRFAM7A siRNA Set Human-specific target validation; Sequence distinct from CHRNA7. |
View CHRFAM7A Products |
| Related Target | CHRNA4 (Neuronal AChR Alpha-4) Key counter-screening target for subtype selectivity. |
View CHRNA4 Products |
| Related Target | CHRNB2 (Neuronal AChR Beta-2) Crucial for assessing off-target CNS effects. |
View CHRNB2 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Human-specific CHRFAM7A biology (no rodent/cyno ortholog) | Human-specific CHRFAM7A Lentivirus & siRNA; Sequence Verified against human genome reference GRCh38. |
| Dominant negative mechanism validation | Dual-expression stable cell line construction supported; High-titer Lentivirus >1x10^8 TU/mL for calcium flux assays. |
| Ion channel functional integrity | Full-length ORF preserves transmembrane domains; HEK293 expression system for native-like membrane insertion. |
| Selectivity vs. other nAChR subunits | Orthologous subunit panels (CHRNA4, CHRNB2) available for cross-reactivity screening; Sequence Verified. |
| Lack of Human-Specific Controls | CHRFAM7A-specific siRNA and ORF targets for loss-of-function studies; Endotoxin controlled. |
| Complex Membrane Protein Expression | Lentivirus Premade Particles for efficient, stable cell line construction to preserve native conformation. |
Live CHRNA7/CHRFAM7A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ CHRFAM7A Specific Trials
- ➤ Latest Resistance Research
- ➤ CHRFAM7A Disease Association
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for alpha-7 nicotinic acetylcholine receptor (nAChR) therapeutics is intensifying, with renewed focus on the human-specific CHRFAM7A fusion protein as a modulator of receptor function. While early efforts focused on direct agonists for schizophrenia and Alzheimer's disease, first-generation agonists faced challenges due to rapid receptor desensitization and the lack of human-specific models. The field is now shifting toward Positive Allosteric Modulators (PAMs) to avoid desensitization, and toward antisense oligonucleotides (ASOs) that suppress CHRFAM7A-mediated dominant negative regulation. Furthermore, the human-specific duplication/fusion gene CHRFAM7A acts as a dominant negative regulator, complicating translational models. Future development relies heavily on precisely understanding target engagement in the presence of CHRFAM7A for both CNS and peripheral inflammatory indications, requiring human-specific cellular models due to the absence of CHRFAM7A orthologs in rodent species.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Alpha-7 Agonist / PAM | AbbVie, Forum Pharma, AstraZeneca, Novartis, Targacept | Schizophrenia (Cognition), Alzheimer's | Receptor Desensitization Assays & Calcium Flux in CHRFAM7A-co-expressing cells (Need Stable Cell Lines & Human-specific Lentivirus) |
| Antisense Oligonucleotide (ASO) | Ionis, Biogen, Academic Consortia | Schizophrenia (CHRFAM7A suppression) | CHRFAM7A-specific cell lines and siRNA validation tools (Sequence Verified) |
| Allosteric Modulator | Bayer, Lundbeck | Neuroinflammation, Ulcerative Colitis | Electrophysiology-ready cell lines (HEK293 stable expression) |
| Targeted Protein Degraders / Abs | Early Stage | Neuroinflammation | Binding & Internalization (Need Sequence-Verified ECD/Lentivirus) |
| Biologic (Peripheral) | Emerging Biotech | Ulcerative Colitis, Pain | Flow Cytometry validation on CHRNA7-expressing cells |